A GLP-1 lowers blood sugar largely by amplifying the insulin response you already produce and damping the hormone that raises glucose. Both effects are glucose-dependent: when your sugar is not high, they largely stand down. That is why these drugs cause remarkably little hypoglycemia by themselves.
Insulin and sulfonylureas have no such brake. They push insulin out whether or not it is wanted. Layer a GLP-1 on top without touching them and the combination becomes the danger. Every one of these labels warns about it, and it is why something usually has to come down before the GLP-1 goes up.
What to do with each
| Medication | Examples | Typically |
|---|---|---|
| Long-acting insulin | Lantus, Tresiba, Toujeo, Levemir, Basaglar | Comes down, commonly by about a fifth to a quarter at the start, and further if your numbers are already at target. |
| Mealtime insulin | Humalog, NovoLog, Apidra, Lyumjev, Fiasp | Comes down more, often by a quarter to a half, because you are about to eat less. Some people stop it altogether once the GLP-1 reaches a working dose, and one trial replaced basal-bolus insulin with a single weekly combination injection. |
| Sulfonylureas | Glipizide, glimepiride, glyburide | Often stopped, or roughly halved if kept. This is the highest-hypoglycemia oral class, and adding a GLP-1 is a natural moment to reconsider it. |
| Meglitinides | Repaglinide, nateglinide | Same logic as sulfonylureas — halved or stopped. |
| Metformin | Glucophage, Glumetza, Fortamet | Unchanged. Almost no hypoglycemia risk of its own and a natural partner to a GLP-1. |
| SGLT2 inhibitors | Jardiance, Farxiga, Invokana | Unchanged. Different mechanism, no shared hypoglycemia risk, and heart and kidney benefits of their own. |
| DPP-4 inhibitors | Januvia, Tradjenta, Onglyza | Stopped. They work on the same incretin pathway a GLP-1 now occupies far more powerfully, so they add nothing. |
| Pioglitazone | Actos | Unchanged, though fluid retention can disguise weight progress. |
| Another GLP-1 | Victoza, Saxenda, Trulicity, Byetta | One stops before the other starts. The Wegovy, Zepbound and Saxenda labels say combining one with any other GLP-1 is not recommended. |
On those percentages. The labels themselves say to consider reducing the insulin or secretagogue dose without naming a figure. The numbers above come from common clinical practice, and your prescriber will adjust to your own readings. Do not change insulin on the strength of a reference card.
Recognizing a hypo
The early signs are physical and easy to dismiss as something else.
- Shaking or trembling hands, usually the first sign.
- Cold sweat or clammy skin with no reason to be sweating.
- Confusion, trouble concentrating, slurred words.
- Dizziness or feeling about to faint.
- A pounding or racing heart.
- Blurred vision, sudden irritability, sudden hunger, headache.
Treat it with roughly 15 to 20 grams of fast sugar: a small glass of juice, a few glucose tablets, a spoon of honey or a handful of hard candy. Wait a quarter of an hour, test again, and repeat if you are still below 70 mg/dL.
Checking it is working
Standard practice is an A1C every three months until you are at target, then twice a year. After a GLP-1 goes in, most prescribers look sooner, with a fasting glucose or a continuous-monitor snapshot at four to eight weeks, to catch over-correction before the formal three-month reading.
That first proper A1C tells you whether the reduction you made at the start was right, insufficient, or too much.
Call your prescriber if
- A severe hypo. Passing out, a seizure, or needing someone else to help you. A single one warrants a same-day call.
- Three or more mild lows inside a week, even ones you handled yourself. The other drug is too high.
- A1C drifting under 6.0% while still on insulin or a sulfonylurea. It looks like success but carries real risk.
- Fasting glucose under 80 mg/dL for a week or more. The basal insulin needs to come down again.
- Readings below 60 mg/dL that you cannot feel at all. Losing hypo awareness means the regimen needs rethinking now.
What this does not cover
Diabetes co-medication only. It does not cover the non-diabetes interactions, such as how a slowed stomach affects the contraceptive pill, levothyroxine timing or warfarin monitoring. Nor type 1 diabetes, diabetes in pregnancy, children, or ketoacidosis planning. Sick days and surgery have their own page.
Nothing here is a reason to change an insulin dose on your own. Use it to prepare for that conversation with your prescriber.
Where to go next
- All cheat sheets, the full reference library.
- Sick-day guide, on holding doses during illness, dehydration and surgery.
- Pregnancy and contraception covers the other interaction people miss.
- Brand names against molecules explains why the diabetes and weight versions of one drug are priced so differently.